Free Trial

CORDA Investment Management LLC. Increases Stake in Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logo with Medical background

CORDA Investment Management LLC. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 207,755 shares of the company's stock after acquiring an additional 3,538 shares during the quarter. Johnson & Johnson accounts for 2.7% of CORDA Investment Management LLC.'s holdings, making the stock its 16th largest position. CORDA Investment Management LLC.'s holdings in Johnson & Johnson were worth $34,454,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of JNJ. MRP Capital Investments LLC boosted its stake in Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after acquiring an additional 65 shares during the last quarter. Syverson Strege & Co boosted its stake in Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after acquiring an additional 65 shares during the last quarter. MBA Advisors LLC boosted its stake in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after acquiring an additional 68 shares during the last quarter. Sovereign Financial Group Inc. boosted its stake in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after acquiring an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc boosted its stake in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after acquiring an additional 69 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on JNJ. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Royal Bank Of Canada reissued an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 5th. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $171.00.

Check Out Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Price Performance

JNJ stock traded up $1.44 during midday trading on Thursday, reaching $157.72. The company had a trading volume of 6,719,599 shares, compared to its average volume of 8,053,055. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market capitalization of $379.48 billion, a P/E ratio of 17.54, a P/E/G ratio of 2.36 and a beta of 0.41. The firm has a 50-day moving average price of $153.67 and a 200-day moving average price of $154.27.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.30%. Johnson & Johnson's dividend payout ratio is 57.84%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines